These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 24331481)
1. Re: urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the canary prostate active surveillance study. Taneja SS J Urol; 2014 Jan; 191(1):75-6. PubMed ID: 24331481 [No Abstract] [Full Text] [Related]
2. Re: Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance Study. Taneja SS J Urol; 2013 Nov; 190(5):1764. PubMed ID: 24120780 [No Abstract] [Full Text] [Related]
3. Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance Study. Lin DW; Newcomb LF; Brown EC; Brooks JD; Carroll PR; Feng Z; Gleave ME; Lance RS; Sanda MG; Thompson IM; Wei JT; Nelson PS; Clin Cancer Res; 2013 May; 19(9):2442-50. PubMed ID: 23515404 [TBL] [Abstract][Full Text] [Related]
4. Clinical Use of PCA3 and TMPRSS2:ERG Urinary Biomarkers in African-American Men Undergoing Prostate Biopsy. Feibus AH; Sartor O; Moparty K; Chagin K; Kattan MW; Ledet E; Levy J; Lee B; Thomas R; Silberstein JL J Urol; 2016 Oct; 196(4):1053-60. PubMed ID: 27140073 [TBL] [Abstract][Full Text] [Related]
5. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment. Tomlins SA; Day JR; Lonigro RJ; Hovelson DH; Siddiqui J; Kunju LP; Dunn RL; Meyer S; Hodge P; Groskopf J; Wei JT; Chinnaiyan AM Eur Urol; 2016 Jul; 70(1):45-53. PubMed ID: 25985884 [TBL] [Abstract][Full Text] [Related]
6. Evaluation of urinary prostate cancer antigen-3 (PCA3) and TMPRSS2-ERG score changes when starting androgen-deprivation therapy with triptorelin 6-month formulation in patients with locally advanced and metastatic prostate cancer. Martínez-Piñeiro L; Schalken JA; Cabri P; Maisonobe P; de la Taille A; BJU Int; 2014 Oct; 114(4):608-16. PubMed ID: 24806330 [TBL] [Abstract][Full Text] [Related]
7. Performance of PCA3 and TMPRSS2:ERG urinary biomarkers in prediction of biopsy outcome in the Canary Prostate Active Surveillance Study (PASS). Newcomb LF; Zheng Y; Faino AV; Bianchi-Frias D; Cooperberg MR; Brown MD; Brooks JD; Dash A; Fabrizio MD; Gleave ME; Liss M; Morgan TM; Thompson IM; Wagner AA; Carroll PR; Nelson PS; Lin DW Prostate Cancer Prostatic Dis; 2019 Sep; 22(3):438-445. PubMed ID: 30664734 [TBL] [Abstract][Full Text] [Related]
8. Urinary Biomarkers for Prostate Cancer. Giunchi F; Ciccarese C; Montironi R; Scarpelli M; Lopez-Beltran A; Cheng L; Moch H; Massari F; Fiorentino M Curr Drug Metab; 2017 Oct; 18(8):723-726. PubMed ID: 28524004 [TBL] [Abstract][Full Text] [Related]
9. Comprehensive assessment for novel prostate cancer markers in the prostate-specific antigen era: focusing on Asians and Asian countries. Okihara K; Ochiai A; Kamoi K; Fujizuka Y; Miki T; Ito K Int J Urol; 2015 Apr; 22(4):334-41. PubMed ID: 25827049 [TBL] [Abstract][Full Text] [Related]
10. Incorporation of Urinary Prostate Cancer Antigen 3 and TMPRSS2:ERG into Prostate Cancer Prevention Trial Risk Calculator. Ankerst DP; Goros M; Tomlins SA; Patil D; Feng Z; Wei JT; Sanda MG; Gelfond J; Thompson IM; Leach RJ; Liss MA Eur Urol Focus; 2019 Jan; 5(1):54-61. PubMed ID: 29422418 [TBL] [Abstract][Full Text] [Related]
11. Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer. Hessels D; Smit FP; Verhaegh GW; Witjes JA; Cornel EB; Schalken JA Clin Cancer Res; 2007 Sep; 13(17):5103-8. PubMed ID: 17785564 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of tissue PCA3 expression in prostate cancer by RNA in situ hybridization--a correlative study with urine PCA3 and TMPRSS2-ERG. Warrick JI; Tomlins SA; Carskadon SL; Young AM; Siddiqui J; Wei JT; Chinnaiyan AM; Kunju LP; Palanisamy N Mod Pathol; 2014 Apr; 27(4):609-20. PubMed ID: 24072184 [TBL] [Abstract][Full Text] [Related]
13. Racial Variation in the Utility of Urinary Biomarkers PCA3 and T2ERG in a Large Multicenter Study. O'Malley PG; Nguyen DP; Al Hussein Al Awamlh B; Wu G; Thompson IM; Sanda M; Rubin M; Wei JT; Lee R; Christos P; Barbieri C; Scherr DS J Urol; 2017 Jul; 198(1):42-49. PubMed ID: 28115190 [TBL] [Abstract][Full Text] [Related]
14. Prostate cancer-derived urine exosomes: a novel approach to biomarkers for prostate cancer. Nilsson J; Skog J; Nordstrand A; Baranov V; Mincheva-Nilsson L; Breakefield XO; Widmark A Br J Cancer; 2009 May; 100(10):1603-7. PubMed ID: 19401683 [TBL] [Abstract][Full Text] [Related]
15. A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer. Laxman B; Morris DS; Yu J; Siddiqui J; Cao J; Mehra R; Lonigro RJ; Tsodikov A; Wei JT; Tomlins SA; Chinnaiyan AM Cancer Res; 2008 Feb; 68(3):645-9. PubMed ID: 18245462 [TBL] [Abstract][Full Text] [Related]
16. Study of genetic and epigenetic alterations in urine samples as diagnostic markers for prostate cancer. Dimitriadis E; Kalogeropoulos T; Velaeti S; Sotiriou S; Vassiliou E; Fasoulis L; Klapsas V; Synesiou M; Apostolaki A; Trangas T; Pandis N Anticancer Res; 2013 Jan; 33(1):191-7. PubMed ID: 23267145 [TBL] [Abstract][Full Text] [Related]
17. Correlation of urine TMPRSS2:ERG and PCA3 to ERG+ and total prostate cancer burden. Young A; Palanisamy N; Siddiqui J; Wood DP; Wei JT; Chinnaiyan AM; Kunju LP; Tomlins SA Am J Clin Pathol; 2012 Nov; 138(5):685-96. PubMed ID: 23086769 [TBL] [Abstract][Full Text] [Related]
18. Urine TMPRSS2: ERG Fusion Transcript as a Biomarker for Prostate Cancer: Literature Review. Sanguedolce F; Cormio A; Brunelli M; D'Amuri A; Carrieri G; Bufo P; Cormio L Clin Genitourin Cancer; 2016 Apr; 14(2):117-21. PubMed ID: 26774207 [TBL] [Abstract][Full Text] [Related]
19. Molecular diagnosis of prostate cancer: PCA3 and TMPRSS2:ERG gene fusion. Salagierski M; Schalken JA J Urol; 2012 Mar; 187(3):795-801. PubMed ID: 22245323 [TBL] [Abstract][Full Text] [Related]